ELUTIA INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
ELUT$0.93+11.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In Thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Net loss | | $(7,469) | $(3,933) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | |||
| Depreciation and amortization | | 330 | 868 | |||
| Gain on sale of Orthobiologics Business | | (425) | — | |||
| Loss (gain) on revaluation of warrant liability | | 1,655 | (5,187) | |||
| Amortization of deferred financing costs and debt discount | | — | 53 | |||
| Interest expense recorded as additional revenue interest obligation and long-term debt | | 145 | 702 | |||
| Stock-based compensation | | 931 | 1,211 | |||
| Changes in right-of-use assets and lease liabilities and lease incentives received | | | 320 | | | (103) |
| Changes in operating assets and liabilities: | | | | | ||
| Accounts receivable | | (334) | (584) | |||
| Inventory | | (40) | (375) | |||
| Receivables of litigation costs | | | (502) | | | 867 |
| Prepaid expenses and other | | 241 | 449 | |||
| Accounts payable and accrued expenses | | 542 | (225) | |||
| Contingent liability for legal proceedings | | | (3,225) | | | (2,624) |
| Net cash used in operating activities | | (7,831) | (8,881) | |||
| INVESTING ACTIVITIES: | | | | |||
| Proceeds from sale of Orthobiologics Business | | | 425 | | | — |
| Expenditures for property and equipment | | (459) | (278) | |||
| Net cash used in investing activities | | (34) | (278) | |||
| FINANCING ACTIVITIES: | | | | |||
| Proceeds from direct registered offering and warrants, net of offering costs | | | — | | | 13,796 |
| Repayments of insurance premium financings | | | — | | | (446) |
| Payments for taxes upon vesting of restricted stock units | | | (44) | | | (152) |
| Proceeds from stock option exercises and issuance of common stock under ESPP | | 47 | 80 | |||
| Net cash provided by financing activities | | 3 | 13,278 | |||
| | | | | | | |
| Net (decrease) increase in cash and cash equivalents | | (7,862) | 4,119 | |||
| | | | | | | |
| Cash and cash equivalents, beginning of period | | 36,350 | 13,239 | |||
| Cash and cash equivalents, end of period | | $28,488 | $17,358 | |||
| | | | | | | |
| Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: | | | | |||
| Cash paid for interest | | $— | $526 | |||
| Conversion of Prefunded Warrants to common stock | | $1,390 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.